The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
|Articles|November 1, 2003
Study recommends 4-year screening interval for PCa
Author(s)Cheryl Guttman Krader, BS, Pharm
Rotterdam, Netherlands-Four years is a reasonable interval for prostatecancer screening, concluded investigators from the European Randomized Studyof Screening for Prostate Cancer (ERSPC).
Advertisement
Advertisement
Related to this article
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
A decision is expected by the fourth quarter of 2026.
Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
2
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5